Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PreventiveMD vs Revel RX

PreventiveMD
Graded #53

Lower grade

vs+1.2000000000000028
Revel RX
Graded #47

Higher grade

The verdict

Revel RX takes it — 77.3/100 to 76.1/100, but only just.

Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier. PreventiveMD is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRevel RX +12
84
96
Dose & formulationPreventiveMD +10
82
72
Clinical oversightRevel RX +2
82
84
Labs & monitoringEven
53
53
FulfillmentPreventiveMD +2
83
81
Contract termsEven
55
55
PreventiveMD · left barRevel RX · right bar

The numbers

MetricPreventiveMDRevel RX
WeighScore76.1/10077.3/100
GradeCC+
Scorecard rank#53#47
Semaglutide$83/mo (starting dose, compounded)$89/mo (all doses, compounded)
Tirzepatide$97/mo (starting dose, compounded)$155/mo (all doses, compounded)
Coverage36 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
PreventiveMD

Graded #53 · C

Strengths

  • Compounded semaglutide from $83/mo and tirzepatide from $97/mo, billed as one all-in monthly price
  • Brand Wegovy, Zepbound, and Foundayo (oral GLP-1) available on the same platform
  • US-licensed provider reviews requests within 24 hours — no video visit required
  • You aren't charged until a provider approves; checkout places an authorization hold only
  • LegitScript-certified; works exclusively with state-licensed US 503A compounding pharmacies

Where it loses points

  • Individual compounding pharmacy partners are not publicly named
  • Not available in 14 states + DC, including New York, New Jersey, Virginia, and Wisconsin
  • Brand Wegovy, Zepbound, and Foundayo require a $49/mo membership fee on top of medication cost
  • 'As low as' pricing — actual monthly cost can be higher depending on your plan
  • Orders become non-refundable once provider review or pharmacy fulfillment begins
Revel RX

Graded #47 · C+

Strengths

  • Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
  • LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
  • Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
  • Free overnight cold shipping included; no hidden fees or dose-based price increases
  • Clinical review by MD Integrations, an independent medical group, before any prescription is issued

Where it loses points

  • States served are not publicly listed; eligible states requires completing intake to confirm coverage
  • No labs, coaching, or ongoing health support disclosed in any public materials
  • Compounded medications are not FDA-approved (site discloses this)
  • Newer brand with limited public patient reviews or Trustpilot rating
  • Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard